Bococizumab

Jump to navigation Jump to search
Pharmacologic interventions for PCSK9 Adapted from Journal of the American College of Cardiology, 62(16): 1401-1408[1]

For a review of all PCSK9 inhibitors please click here

WikiDoc Resources for Bococizumab

Articles

Most recent articles on Bococizumab

Most cited articles on Bococizumab

Review articles on Bococizumab

Articles on Bococizumab in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bococizumab

Images of Bococizumab

Photos of Bococizumab

Podcasts & MP3s on Bococizumab

Videos on Bococizumab

Evidence Based Medicine

Cochrane Collaboration on Bococizumab

Bandolier on Bococizumab

TRIP on Bococizumab

Clinical Trials

Ongoing Trials on Bococizumab at Clinical Trials.gov

Trial results on Bococizumab

Clinical Trials on Bococizumab at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bococizumab

NICE Guidance on Bococizumab

NHS PRODIGY Guidance

FDA on Bococizumab

CDC on Bococizumab

Books

Books on Bococizumab

News

Bococizumab in the news

Be alerted to news on Bococizumab

News trends on Bococizumab

Commentary

Blogs on Bococizumab

Definitions

Definitions of Bococizumab

Patient Resources / Community

Patient resources on Bococizumab

Discussion groups on Bococizumab

Patient Handouts on Bococizumab

Directions to Hospitals Treating Bococizumab

Risk calculators and risk factors for Bococizumab

Healthcare Provider Resources

Symptoms of Bococizumab

Causes & Risk Factors for Bococizumab

Diagnostic studies for Bococizumab

Treatment of Bococizumab

Continuing Medical Education (CME)

CME Programs on Bococizumab

International

Bococizumab en Espanol

Bococizumab en Francais

Business

Bococizumab in the Marketplace

Patents on Bococizumab

Experimental / Informatics

List of terms related to Bococizumab

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bococizumab (PF-04950615; RN316) is a humanized monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 and is an investigational agent for the reduction of LDL-C levels in patients with hypercholesterolemia.

Properties

Major Trials

Phase II Trials

Phase III Trials

References

  1. Urban, D.; Pöss, J.; Böhm, M.; Laufs, U. (2013). "Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis". J Am Coll Cardiol. 62 (16): 1401–8. doi:10.1016/j.jacc.2013.07.056. PMID 23973703. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources